- Home
- LCTX vs INMB Comparison
LCTX vs INMB Comparison
Compare LCTX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- INMB
- Stock Information
- Founded
- LCTX 1990
- INMB 2015
- Country
- LCTX United States
- INMB United States
- Employees
- LCTX N/A
- INMB N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- INMB Health Care
- Exchange
- LCTX Nasdaq
- INMB Nasdaq
- Market Cap
- LCTX 110.2M
- INMB 112.0M
- IPO Year
- LCTX N/A
- INMB 2019
- Fundamental
- Price
- LCTX $0.55
- INMB $4.40
- Analyst Decision
- LCTX Strong Buy
- INMB Strong Buy
- Analyst Count
- LCTX 4
- INMB 2
- Target Price
- LCTX $5.25
- INMB $21.00
- AVG Volume (30 Days)
- LCTX 3.9M
- INMB 215.6K
- Earning Date
- LCTX 11-14-2024
- INMB 10-31-2024
- Dividend Yield
- LCTX N/A
- INMB N/A
- EPS Growth
- LCTX N/A
- INMB N/A
- EPS
- LCTX N/A
- INMB N/A
- Revenue
- LCTX $8,719,000.00
- INMB $42,000.00
- Revenue This Year
- LCTX N/A
- INMB N/A
- Revenue Next Year
- LCTX $123.52
- INMB N/A
- P/E Ratio
- LCTX N/A
- INMB N/A
- Revenue Growth
- LCTX N/A
- INMB N/A
- 52 Week Low
- LCTX $0.48
- INMB $4.32
- 52 Week High
- LCTX $1.61
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- LCTX 41.03
- INMB 37.57
- Support Level
- LCTX $0.48
- INMB $4.74
- Resistance Level
- LCTX $0.57
- INMB $5.16
- Average True Range (ATR)
- LCTX 0.05
- INMB 0.38
- MACD
- LCTX 0.01
- INMB -0.05
- Stochastic Oscillator
- LCTX 48.36
- INMB 5.56
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.